dc.contributor.author | O'Byrne, Ken | en |
dc.contributor.author | Gately, Kathy | en |
dc.contributor.author | Barr, Martin | en |
dc.contributor.author | Baird, Anne-Marie | en |
dc.date.accessioned | 2014-09-08T14:33:31Z | |
dc.date.available | 2014-09-08T14:33:31Z | |
dc.date.issued | 2013 | en |
dc.date.submitted | 2013 | en |
dc.identifier.citation | Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K., Targeting nuclear factor-kappa B to overcome resistance to chemotherapy., Frontiers in oncology, 3, 2013, 120 | en |
dc.identifier.issn | 2234-943X | en |
dc.identifier.other | Y | en |
dc.identifier.uri | http://hdl.handle.net/2262/71225 | |
dc.description | PUBLISHED | en |
dc.description.abstract | Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-κB pathway. NF-κB is a key transcription factor, playing a role in the development and progression of cancer and chemoresistance through the activation of a multitude of mediators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signaling by pharmacological intervention will be addressed. | en |
dc.format.extent | 120 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Frontiers in oncology | en |
dc.relation.ispartofseries | 3 | en |
dc.rights | Y | en |
dc.subject | oncogene | en |
dc.subject | apoptosis | en |
dc.subject | resistance | en |
dc.subject | chemotherapy | en |
dc.subject | cisplatin | en |
dc.subject | cancer | en |
dc.subject | NF-κB | en |
dc.title | Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/obyrneke | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/gatelyk | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/bairda | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/barrma | en |
dc.identifier.rssinternalid | 96237 | en |
dc.identifier.doi | http://dx.doi.org/10.3389/fonc.2013.00120 | en |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTag | Biomedical sciences | en |